The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data
- PMID: 17728050
- DOI: 10.1016/j.eururo.2007.08.005
The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data
Abstract
Objectives: To assess the usefulness of the phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of premature ejaculation (PE) and to describe possible mechanisms to explain their effect.
Methods: A MedLine search was performed for peer-reviewed articles on the role of PDE5-Is in managing PE. No meta-analysis method was used.
Results: Five manuscripts that examined the efficacy of PDE5-Is in the treatment of PE were retrieved. Three studies used sildenafil as monotherapy and two used it in combination with a serotonin selective reuptake inhibitor (SSRI). Three studies demonstrated a beneficial effect of sildenafil in the treatment of PE, as measured by intravaginal ejaculatory latency time (IELT) and by different questionnaires assessing the patients' subjective feelings of ejaculatory control, sexual satisfaction, and anxiety. One study showed the superiority of sildenafil compared to other modalities. Two studies showed that combination therapy of paroxetine and sildenafil was better than paroxetine alone. One study did not demonstrate a beneficial effect of sildenafil in prolonging IELT, but showed that sildenafil improved patients' perception of ejaculatory control. Another study showed that topical anesthetics were better than sildenafil in the treatment of PE but did not use IELT or a validated questionnaire to measure the efficacy of treatment. Several possible mechanisms could explain effectiveness of the PDE5-Is for treatment of PE: centrally, through the effect on the nitric oxide/cyclic guanosine monophosphate pathway; peripherally by causing relaxation of smooth muscle in the vas deferens, seminal vesicles, prostate, and urethra and inhibition of adrenergic transmission; or locally by inducing peripheral analgesia. Another possibility might be prolongation of the duration of erection.
Conclusions: Encouraging evidence supports the role of PDE5-Is for treating PE. Possible therapeutic mechanisms of action of PDE5-Is are multiple and complex and include central and peripheral effects. A large population, multicenter, randomized, double-blind, placebo-controlled study is needed to elucidate the efficacy of PDE5-Is in the treatment of PE.
Similar articles
-
Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.Eur Urol Focus. 2017 Feb;3(1):119-129. doi: 10.1016/j.euf.2016.02.001. Epub 2016 Feb 19. Eur Urol Focus. 2017. PMID: 28720356 Free PMC article.
-
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.BJU Int. 2011 Apr;107(8):1274-7. doi: 10.1111/j.1464-410X.2010.09646.x. Epub 2010 Sep 7. BJU Int. 2011. PMID: 21929518 Clinical Trial.
-
Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?Int J Impot Res. 2011 Jan-Feb;23(1):17-23. doi: 10.1038/ijir.2010.34. Epub 2011 Jan 27. Int J Impot Res. 2011. PMID: 21270821 Review.
-
Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.BJU Int. 2006 Aug;98(2):259-72. doi: 10.1111/j.1464-410X.2006.06290.x. BJU Int. 2006. PMID: 16879663 Review.
-
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.Int J Androl. 2006 Oct;29(5):503-09. doi: 10.1111/j.1365-2605.2006.00689.x. Int J Androl. 2006. PMID: 16573707 Review.
Cited by
-
Combined on-demand sildenafil citrate and tramadol hydrochloride is an effective and safe treatment for premature ejaculation: A randomized placebo-controlled double-blind clinical trial.Arab J Urol. 2023 Nov 30;22(2):89-95. doi: 10.1080/20905998.2023.2287869. eCollection 2024. Arab J Urol. 2023. PMID: 38481408 Free PMC article.
-
Current and emerging treatment options for premature ejaculation.Nat Rev Urol. 2022 Nov;19(11):659-680. doi: 10.1038/s41585-022-00639-5. Epub 2022 Aug 25. Nat Rev Urol. 2022. PMID: 36008555 Review.
-
Phosphodiesterase-5 Inhibitors for Premature Ejaculation: Systematic Review and Meta-Analysis of Placebo-Controlled Trials.Am J Mens Health. 2020 May-Jun;14(3):1557988320916406. doi: 10.1177/1557988320916406. Am J Mens Health. 2020. PMID: 32375542 Free PMC article.
-
Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.Eur Urol Focus. 2017 Feb;3(1):119-129. doi: 10.1016/j.euf.2016.02.001. Epub 2016 Feb 19. Eur Urol Focus. 2017. PMID: 28720356 Free PMC article.
-
Emerging and investigational drugs for premature ejaculation.Transl Androl Urol. 2016 Aug;5(4):487-501. doi: 10.21037/tau.2016.04.02. Transl Androl Urol. 2016. PMID: 27652222 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical